The kringle 1 domain of hepatocyte growth factor has antiangiogenic and antitumor cell effects on hepatocellular carcinoma

Cancer Research

Volumn 68, Issue 2, 2008, Pages 404-414

  Shen, Zan ^a   Zhen, Fan Yang ^a   Gao, Yi ^a   Ji, Cheng Li ^b   Hai, Xiao Chen ^c   Ching, Chiu Liu ^a   Poon, Ronnie T P ^a   Sheung, Tat Fan ^a   Luk, John M ^a   Kong, Hung Sze ^a   Tsai, Ping Li ^d   Ren, Bao Gan ^d   Ming, Liang He ^e   Hsiang, Fu Kung ^e   Lin, Marie C M ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b ZHEJIANG UNIVERSITY   (China)

^c TAIZHOU HOSPITAL OF ZHEJIANG PROVINCE   (China)

^d INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; EGFR PROTEIN, RAT; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; ENDOTHELIUM CELL; ENZYME ACTIVATION; IN VITRO STUDY; IN VIVO STUDY; KRINGLE DOMAIN; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; RAT; VIRUS RECOMBINANT; ANIMAL; BUFFALO RAT; CELL CULTURE; CELL CYCLE; CHEMISTRY; DRUG ANTAGONISM; EVALUATION; GENE THERAPY; GENETICS; HUMAN; LIVER TUMOR; MALE; METABOLISM; METASTASIS; MORTALITY; PATHOLOGY; PHYSIOLOGY; SURVIVAL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL PROLIFERATION; CELLS, CULTURED; DEPENDOVIRUS; GENE THERAPY; HEPATOCYTE GROWTH FACTOR; HUMANS; KRINGLES; LIVER NEOPLASMS, EXPERIMENTAL; MALE; NEOPLASM METASTASIS; RATS; RATS, INBRED BUF; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SURVIVAL ANALYSIS;

EID: 39049146233     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2081     Document Type: Article

References (33)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-32.
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
3. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39.
4. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438:932-8.
5. Jubb AM, Oates AJ, Holden S, Koeppen H. Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer 2006;6:626-35.
6. Chavakis T, Athanasopoulos A, Rhee JS, et al. Angiostatin is a novel anti-inflammatory factor by inhibiting leukocyte recruitment. Blood 2005;105:1036-43.
7. Veitonmaki N, Cao R, Wu LH, et al. Endothelial cell surface ATP synthase-triggered caspase-apoptotic pathway is essential for k1-5-induced antiangiogenesis. Cancer Res 2004;64:3679-86.
8. Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M, Nakamura T. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 2000;60:6737-43.
9. Kazuhiko D, Kunio M, Hideo S, Masao T, Toshikazu N. HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett 1997;420:1-6.
10. Yu AS, Keeffe EB. Management of hepatocellular carcinoma. Rev Gastroenterol Disord 2003;3:8-24.
11. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17.
12. Bruix J, Llovet JM. Hepatocellular carcinoma: is surveillance cost effective? Gut 2001;48:149-50.
13. Johnson PJ. Hepatocellular carcinoma: is current therapy really altering outcome? Gut 2002;51:459-62.
14. Zhu AX, Blaszkowsky LS, Hale KE, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:1898-903.
15. Llovet JM, Chen Y, Wurmbach E, etal. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006;131:1758-67.
16. Vejchapipat P, Tangkijvanich P, Theamboonlers A, et al. Association between plasma hepatocyte growth factor and survival in untreated hepatocellular carcinoma. J Gastroenterol 2004;39:1182-8.
17. Xin L, Xu R, Zhang Q, Li TP, Gan RB. Kringle 1 of human hepatocyte growth factor inhibits bovine aortic endothelial cell proliferation stimulated by basic fibroblast growth factor and causes cell apoptosis. Biochem Biophys Res Commun 2000;277:186-90.
18. Hoffmann S, Wunderlich A, Celik I, et al. Paneling human thyroid cancer cell lines for candidate proteins for targeted anti-angiogenic therapy. J Cell Biochem 2006;98:954-65.
19. Kurup A, Lin CW, Murry DJ, et al. Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University. Ann Oncol 2006;17:97-103.
20. Samulski RJ, Chang LS, Shenk T. Helper-free stocks of recombinant adeno-associatd viruses: normal integration does not require viral gene expression. J Virol 1989;63:3822-8.
21. Liu CC, Shen Z, Kung HF, Lin CM. Cancer gene therapy targeting angiogenesis: an updated review. World J Gastroenterol 2006;12:6941-8.
22. Ponnazhagan S, Mahendra G, Kumar S, et al. Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Res 2004;64:1781-7.
23. Merten OW, Geny-Fiamma C, Douar AM. Current issues in adeno-associated viral vector production. Gene Ther 2005;Suppl 1:S51-61.
24. Chen Y, Luk KD, Cheung KM, et al. Gene therapy for bone formation using adeno associated viral bone morphogenetic protein 2 vectors. Gene Ther 2003;10:1345-53.
25. Grimm D, Kern A, Rittner K, Kleinschmidt JA. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther 1998;9:2745-60.
26. Yang ZF, Ho DW, Lam CT, et al. Identification of brain-derived neurotrophic factor as a novel functional protein in hepatocellular carcinoma. Cancer Res 2005;65:219-25.
27. Lum CT, Yang ZF, Li HY, et al. Gold(III) compound is a novel chemocytotoxic agent for hepatocellular carcinoma. Int J Cancer 2006;118:1527-38.
28. Soumaoro T, Uetake H, Higuchi T, et al. Cyclooxygenase-2 expression a significant prognostic indicator for patients with colorectal cancer labile. Clin Cancer Res 2004;10:8465-71.
29. Yang ZF, Wu XB, Tsui TY, et al. Recombinant adeno-associated virus vector: Is it ideal for gene delivery in liver transplantation? Liver Transpl 2003;9:411-20.
30. Rabinowitz JE, Samulski J. Adeno-associated virus expression systems for gene transfer. Curr Opin Biotechnol 1998;9:470-5.
31. Subramanian IV, Bui Nguyen TM, Truskinovsky AM, et al. Adeno-associated virus-mediated delivery of a mutant endostatin in combination with carboplatin treatment inhibits orthotopic growth of ovarian cancer and improves long-term survival. Cancer Res 2006;66:4319-28.
32. Mingozzi F, Schüttrumpf J, Arruda VR, et al. Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector. J Virol 2002;76:10497-502.
33. Baker CH, Kedar D, McCarty MF, et al. Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am J Pathol 2002;161:929-38.